iLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex’s obese MASH hamster and mouse models – review the manuscript here.

If you wish to evaluate your novel therapies using Physiogenex CRO services and models, feel free to contact us tor discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.